Assembly Biosciences Outlines Anticipated 2022 Pipeline Development Milestones
04. Januar 2022 08:00 ET
|
Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03. Dezember 2021 17:00 ET
|
Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 03, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...
Assembly Biosciences Presents New Data at AASLD The Liver Meeting™ Highlighting the Progress of its HBV Core Inhibitor Portfolio
12. November 2021 08:00 ET
|
Assembly Biosciences, Inc.
Newly selected preclinical core inhibitor candidate, ABI-4334, demonstrates single-digit nanomolar potency against both pgRNA encapsidation and cccDNA formation ABI-H3733 shows favorable...
Assembly Biosciences Reports Third Quarter 2021 Financial Results and Recent Highlights
04. November 2021 16:05 ET
|
Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...
Assembly Biosciences Abstracts Selected for Presentation at the Upcoming AASLD The Liver Meeting®
01. November 2021 10:32 ET
|
Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...
Antios Therapeutics and Assembly Biosciences Announce Clinical Collaboration Agreement to Evaluate the Combination of ATI-2173 and Vebicorvir in Patients with Chronic Hepatitis B Virus Infection
19. Oktober 2021 07:30 ET
|
Assembly Biosciences, Inc.
MENDHAM, N.J., and SOUTH SAN FRANCISCO, Calif, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Antios Therapeutics, Inc. and Assembly Biosciences, Inc. (Nasdaq: ASMB) today announced that the companies have...
Assembly Bio Announces October Conference Participation
06. Oktober 2021 08:00 ET
|
Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01. Oktober 2021 18:04 ET
|
Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...
Assembly Bio Announces Decision to Discontinue Clinical Development of ABI-H2158
01. September 2021 16:02 ET
|
Assembly Biosciences, Inc.
--Decision follows observation of elevated alanine transaminase (ALT) levels in Phase 2 study--Company will focus on advancing ongoing triple combination studies and earlier pipeline candidates SOUTH...
Assembly Bio Selects Fourth HBV Core Inhibitor Candidate for Advancement Into Clinical Development
18. August 2021 08:00 ET
|
Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...